Molecular Partners and Orano Med modify agreement, focusing on four Radio-DARPin programs for targeted cancer therapy.

Molecular Partners and Orano Med have modified their co-development agreement to focus on four Radio-DARPin programs, allowing each company to commercialize two programs. Molecular Partners will lead the commercialization of the DLL3-targeting candidate MP0712, with first-in-human studies expected in 2025, pending regulatory approval. The Radio-DARPin platform aims to enhance targeted cancer therapy through efficient drug discovery and reduced off-target effects.

October 22, 2024
7 Articles